Organ Dysfunction/Mortality is under clinical development by BioAegis Therapeutics and currently in Phase II for Sepsis. According to GlobalData, Phase II drugs for Sepsis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Organ Dysfunction/Mortality’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Organ Dysfunction/Mortality overview
Recombinant plasma gelsolin (pGSN) is under development for the treatment of acute respiratory distress syndrome (ARDS), sepsis, coronavirus disease 2019 (COVID-19) pneumonia, idiopathic bronchiectasis and acute lung injury. It is administered through intravenous route in the form of solution. The drug candidate is an endogenous human protein and a key component of the innate immune system being developed based on plasma gelsolin technology.
It was also under development for the treatment of chronic lung injury and unspecified influenza infections.
BioAegis Therapeutics overview
BioAegis Therapeutics that involves in developing therapeutics for infectious, inflammatory and degenerative diseases based on the platform of plasma gelsolin. The company is headquartered in North Brunswick, New Jersey, the US.
For a complete picture of Organ Dysfunction/Mortality’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
